Pregabalin Capsule
Product Images NDC 68788-8360

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 68788-8360). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Schematic, Timelinedescription Automatically Generated (E8e272a4 C181 4573 822b 2bb315b6ad37 00)

The label for Pregabalin Capsules 100 mg (CV), a generic for Lyrica, displays that each capsule contains 100 mg of pregabalin. It includes storage instructions and legal cautions, with the labeler noted as Ascend Laboratories, LLC under Preferred Pharmaceuticals, Inc. The label is predominantly yellow and includes space for batch, expiration, and insurance details, along with dosing directions in English and Spanish.*

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

A formula for calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, and serum creatinine in mg/dL, with a multiplication factor of 0.85 for female patients. The formula is presented as a mathematical equation.*

FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

Bar chart showing responder rates (%) in two clinical studies, Study E1 and Study E3, for different doses of Pregabalin compared to placebo. Study E1 includes doses from 50 mg/day to 600 mg/day administered BID; responder rates increase from 14% (placebo) up to 51% at 600 mg/day. Study E3 compares placebo to 600 mg/day given BID and TID, with responder rates of 9%, 43%, and 49%, respectively. Statistically significant results versus placebo are marked with an asterisk.*

FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day for Pregabalin across three studies with different dosing schedules (BID and TID). The graph shows increasing seizure reduction with higher doses, with p-values indicating statistical significance of results.*

FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, with multiple lines indicating different treatment groups and their response rates.*

FDA Label Image

Study Sci 1 (Pregabalin Image 10)

A line graph comparing the percent of subjects improved versus the percent improvement from baseline to Week 12 BOCF for Pregabalin and Placebo. The x-axis shows percent improvement from >0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100%. Two lines represent Pregabalin and Placebo outcomes across the improvement spectrum.*

FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

A line graph depicting the percent improvement from baseline to Week 16 based on the Brief Pain Inventory-Short Form (BPI-SF). The x-axis shows the percent improvement range from over 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100%. Two curves are displayed: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin consistently showing higher improvement percentages compared to Placebo.*

FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline. The graph compares two groups: patients taking Pregabalin 100 mg three times a day and those receiving a placebo, showing trends over increasing pain improvement percentages.*

FDA Label Image

Study Phn 1 (Pregabalin Image 3)

A line graph depicting the percent of patients improved over time relative to pain baseline. The graph compares the effectiveness of Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day versus placebo, showing different curves for each treatment over a time scale from 0 to 100 units.*

FDA Label Image

Study Phn 2 (Pregabalin Image 4)

A line graph depicting the percent of patients improved against the percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends of patient improvement over a range of pain improvement percentages.*

FDA Label Image

Study Phn 3 (Pregabalin Image 5)

A line graph depicting the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing higher percentages of patient improvement with Pregabalin doses relative to placebo.*

FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares placebo with pregabalin daily doses of 300 mg, 450 mg, and 600 mg, each represented by different lines, illustrating patient response to each treatment level.*

FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR (likely loss to response) over 180 days. It compares Pregabalin (solid line) to placebo (dashed line), with the Y-axis representing estimated percentage of subjects without LTR from 0% to 100% and the X-axis representing days from 0 to 180.*

FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Chemical structure of pregabalin, the active ingredient depicted with molecular bonds and functional groups including an amine and a carboxylic acid.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.